LOGIN  |  REGISTER

BUY $CMPX

Buy $CMPX on TDAmeritrade

Buy $CMPX on ETrade

Buy $CMPX on Public.com

Buy $CMPX on Fidelity

Buy $CMPX on  Robinhood

Buy $CMPX on Webull

Compass Therapeutics to Participate in Upcoming Investor Events

August 30, 2023 | Last Trade: US$1.79 0.09 5.29

BOSTON, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of September 2023.

Details are as follows:

Citi’s 18th Annual BioPharma Conference
Location: Boston, MA
Format: 1x1 Meetings
Date: Thursday, September 7

H.C. Wainwright 25th Annual Global Investment Conference
Location: New York, NY
Format: Presentation
Date: Monday, September 11
Time: 4:00 PM ET
Webcast Link: https://journey.ct.events

Cantor Fitzgerald Global Healthcare Conference
Location: New York, NY
Format: Fireside Chat
Date: Wednesday, September 27
Time: 2:25-2:55 PM ET
Webcast Link: https://wsw.com/webcast/cantor19/cmpx

Virtual/Replay availability: Presentations will be archived for 90 days on Compass’ Events page.

About Compass Therapeutics

Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’ scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at https://www.compasstherapeutics.com.

Investor Contact
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact
Anna Gifford, Communications Manager
This email address is being protected from spambots. You need JavaScript enabled to view it.
617-500-8099

BUY $CMPX

Buy $CMPX on TDAmeritrade

Buy $CMPX on ETrade

Buy $CMPX on Public.com

Buy $CMPX on Fidelity

Buy $CMPX on  Robinhood

Buy $CMPX on Webull

Stock Quote

BUY $CMPX

Buy $CMPX on TDAmeritrade

Buy $CMPX on ETrade

Buy $CMPX on Public.com

Buy $CMPX on Fidelity

Buy $CMPX on  Robinhood

Buy $CMPX on Webull

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE
Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB